creating skin resurfacing via controlled inflammation. Unlike conventional skin peelings which may cause extensive skin exfoliation, controlled skin resurfacing actively promotes an accelerated form of cell regeneration in the different layers of the skin using low concentrations of multiple acids, thereby reducing trauma and superficial irritation. This action is achieved through the mechanism of a unique bio-availability delivery complex (PH-DVC™) that promotes maximum controlled delivery of actives with minimal negative effects normally seen with conventional peelings. These resurfacing systems have been available in Europe for several years, and MDRejuvena, Inc. (San Diego, CA) is now developing the products for use in North America.
The resurfacing treatment systems provide customized treatment options based on the patient’s individual skin tolerability level and include products to treat various skin conditions. Two of the treatments that have been tested in a US clinical experience trial are AGE and MELA. Each of these treatments provides a progressive application system with three levels (strengths) of resurfacing.
A US clinical experience trial enrolled 20 subjects in AGE and 20 subjects in MELA resurfacing protocols. No additional products were permitted. Results of investigator assessment of global improvement rated 81% of subjects with some level of improvement (11% marked, 27% moderate, 43% mild; n=37 subjects). Subject self-assessment ratings were 63% much improved, 20% improved, and 17% no change (n=30 subjects). The procedures were tolerated with no or mild discomfort by 73% of subjects (n=36 subjects).
Subjects who completed participation in the US clinical experience trial and received 3 chemical resurfacing treatments (AGE or MELA) were invited to participate in a continuation trial in which they used a daily regimen of MDRejuvena products for 12 weeks to assess whether the benefits achieved with the chemical resurfacing treatments could be maintained. MDRejuvena products feature Phytochromatic MD® Complex, which is included in the Rejuvaphyl® line of topical products. The active component of Phytochromatic MD® Complex is liposomal sodium copper chlorophyllin complex. This complex has been shown in clinical
Colvanstudies to have multiple activities including anti-aging, anti-inflammatory and antioxidant actions, and has demonstrated improvement in skin condition in women with photodamaged facial skin.5 In addition, studies have demonstrated Phytochromatic MD® Complex to have potent inhibitory effects on hyaluronidase which helps maintain structural integrity in the skin.6
METHODS
Subjects
Subjects who completed participation in a US experience trial of chemical resurfacing treatments (AGE or MELA) were invited to participate in a continuation study to evaluate the effectiveness of MDRejuvena product regimen to maintain the benefits achieved with the facial skin resurfacing treatments. Subjects provided written informed consent prior to receiving the treatments. Efficacy was evaluated by clinical assessments and digital photographs. Subjects also completed a self-assessment questionnaire.
Treatments
Subjects used the following MDRejuvena facial products for 12 weeks:
